Download MendeleyStructure-based design of substituted piperidines as a new class of highly efficacious oral direct Renin inhibitors.
Ehara, T., Irie, O., Kosaka, T., Kanazawa, T., Breitenstein, W., Grosche, P., Ostermann, N., Suzuki, M., Kawakami, S., Konishi, K., Hitomi, Y., Toyao, A., Gunji, H., Cumin, F., Schiering, N., Wagner, T., Rigel, D.F., Webb, R.L., Maibaum, J., Yokokawa, F.(2014) ACS Med Chem Lett 5: 787-792
- PubMed: 25050166
- DOI: https://doi.org/10.1021/ml500137b
- Primary Citation of Related Structures:
4PYV, 4Q1N - PubMed Abstract:
A cis-configured 3,5-disubstituted piperidine direct renin inhibitor, (syn,rac)-1, was discovered as a high-throughput screening hit from a target-family tailored library. Optimization of both the prime and the nonprime site residues flanking the central piperidine transition-state surrogate resulted in analogues with improved potency and pharmacokinetic (PK) properties, culminating in the identification of the 4-hydroxy-3,5-substituted piperidine 31. This compound showed high in vitro potency toward human renin with excellent off-target selectivity, 60% oral bioavailability in rat, and dose-dependent blood pressure lowering effects in the double-transgenic rat model.
Organizational Affiliation:
Novartis Institutes for BioMedical Research , Ohkubo 8, Tsukuba, Ibaraki 300-2611, Japan.
